H01554 | |
H number | H01554 |
Name | Fallopian tube cancer |
Description | Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis. |
Category | Cancer |
Network | - |
Gene | BRCA1 (mutation) [HSA:672] [KO:K10605] BRCA2 (mutation) [HSA:675] [KO:K08775] TP53 (overexpression) [HSA:7157] [KO:K04451] ERBB2 (overexpression) [HSA:2064] [KO:K05083] c-myc (overexpression) [HSA:4609] [KO:K04377] |
Pathogen | - |
Env factor | - |
Carcinogen | - |
Drug | Bevacizumab [DR:D06409] Niraparib tosilate hydrate [DR:D11895] (BRCA-mutated) Mirvetuximab soravtansine [DR:D10954] (folate receptor alpha positive) |
Comment | - |
Other DBs | ICD-11: 2C74 ICD-10: C57.0 MeSH: D005185 |
Reference | PMID:25286779 AUTHORS Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH TITLE Primary fallopian tube cancer: domestic data and up-to-date review. JOURNAL Taiwan J Obstet Gynecol 53:287-92 (2014) DOI:10.1016/j.tjog.2014.07.003 PMID:23622731 AUTHORS Kalampokas E, Kalampokas T, Tourountous I TITLE Primary fallopian tube carcinoma. JOURNAL Eur J Obstet Gynecol Reprod Biol 169:155-61 (2013) DOI:10.1016/j.ejogrb.2013.03.023 PMID:23937438 AUTHORS Nik NN, Vang R, Shih IeM, Kurman RJ TITLE Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. JOURNAL Annu Rev Pathol 9:27-45 (2014) DOI:10.1146/annurev-pathol-020712-163949 PMID:21922146 AUTHORS Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H TITLE Molecular genetics and epidemiology of epithelial ovarian cancer (Review). JOURNAL Oncol Rep 26:1347-56 (2011) DOI:10.3892/or.2011.1456 PMID:24511245 AUTHORS Sama AR, Schilder RJ TITLE Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management. JOURNAL Int J Womens Health 6:149-57 (2014) DOI:10.2147/IJWH.S40889 PMID:7773939 AUTHORS Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC TITLE c-erbB-2 and p53 expression in fallopian tube carcinoma. JOURNAL Cancer 75:2891-6 (1995) DOI:10.1002/1097-0142(19950615)75:12<2891::AID-CNCR2820751216>3.0.CO;2-B PMID:23240669 AUTHORS Vang R, Shih IeM, Kurman RJ TITLE Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. JOURNAL Histopathology 62:44-58 (2013) DOI:10.1111/his.12046 PMID:25315029 AUTHORS Keating GM TITLE Bevacizumab: a review of its use in advanced cancer. JOURNAL Drugs 74:1891-925 (2014) DOI:10.1007/s40265-014-0302-9 |